Powder: -20°C for 3 years | In solvent: -80°C for 1 year
BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 98.00 | |
5 mg | In stock | $ 247.00 | |
10 mg | In stock | $ 396.00 | |
25 mg | In stock | $ 872.00 | |
50 mg | In stock | $ 1,390.00 | |
100 mg | In stock | $ 2,230.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 272.00 |
Description | BAY 2666605 is an orally active inhibitor of PDE3A and PDE3B with IC50s of 87 nM and 50 nM, respectively. BAY 2666605 has anticancer effects. |
In vitro | BAY 2666605 inhibits brain cancer(glioma, more specifically glioblastoma, astrocytoma), breast cancer (ductal carcinoma and adenocarcinoma), cervical cancer, AML(erythroleukemia), lung cancer(NSCLC adenocarcinoma and SCLC), skin cancer(melanoma), esophagus cancer (squamous cell carcinoma), ovarian cancer, (teratocarcinoma, adenocarcinoma), pancreas cancer and prostatic cancer[1]. |
In vivo | In murine xenotransplantation models of human cancer, BAY 2666605 (5 mg/kg; p.o) exhibits anti-tumor efficacy[1]. |
Molecular Weight | 352.28 |
Formula | C17H12F4N2O2 |
CAS No. | 2275774-60-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 245 mg/mL (695.47 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
BAY 2666605 2275774-60-0 Metabolism PDE anticancer effect inhibit orally active BAY-2666605 PDE3A-SLFN12 Complex Phosphodiesterase (PDE) BAY2666605 Inhibitor inhibitor